- Home
- BIIB vs CHWY Comparison
BIIB vs CHWY Comparison
Compare BIIB & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CHWY
- Stock Information
- Founded
- BIIB 1978
- CHWY 2010
- Country
- BIIB United States
- CHWY United States
- Employees
- BIIB N/A
- CHWY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CHWY Catalog/Specialty Distribution
- Sector
- BIIB Health Care
- CHWY Consumer Discretionary
- Exchange
- BIIB Nasdaq
- CHWY Nasdaq
- Market Cap
- BIIB 18.7B
- CHWY 15.3B
- IPO Year
- BIIB 1991
- CHWY 2019
- Fundamental
- Price
- BIIB $144.56
- CHWY $38.01
- Analyst Decision
- BIIB Buy
- CHWY Strong Buy
- Analyst Count
- BIIB 27
- CHWY 24
- Target Price
- BIIB $188.09
- CHWY $45.05
- AVG Volume (30 Days)
- BIIB 1.5M
- CHWY 9.0M
- Earning Date
- BIIB 10-29-2025
- CHWY 09-10-2025
- Dividend Yield
- BIIB N/A
- CHWY N/A
- EPS Growth
- BIIB 31.67
- CHWY N/A
- EPS
- BIIB 10.45
- CHWY 0.35
- Revenue
- BIIB $9,997,000,000.00
- CHWY $12,345,235,000.00
- Revenue This Year
- BIIB $2.00
- CHWY $8.77
- Revenue Next Year
- BIIB N/A
- CHWY $7.09
- P/E Ratio
- BIIB $13.83
- CHWY $109.38
- Revenue Growth
- BIIB 3.36
- CHWY 9.17
- 52 Week Low
- BIIB $110.04
- CHWY $26.28
- 52 Week High
- BIIB $204.18
- CHWY $48.62
- Technical
- Relative Strength Index (RSI)
- BIIB 58.75
- CHWY 47.28
- Support Level
- BIIB $141.12
- CHWY $34.64
- Resistance Level
- BIIB $147.23
- CHWY $43.50
- Average True Range (ATR)
- BIIB 4.56
- CHWY 1.44
- MACD
- BIIB 0.11
- CHWY -0.31
- Stochastic Oscillator
- BIIB 67.64
- CHWY 39.03
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.